Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04204-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Resear…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: To compare the real-world efficacy and safety of bispecific antibodies (BsAbs, PD-1/CTLA-4) versus PD-1 inhibitors (ICIs), each combined with platinum-based chemotherapy ± bevacizumab, as first-line treatment for persistent, recurrent, or metastatic cervical cancer (p/r/m CC). METHODS: In our single-center retrospective matched cohort study, 121 patients treated between January 2021 and February 2025 were recruited. They were divided into two groups: the bispecific antibody combination group and the PD-1 inhibitor combination group. After propensity score matching (PSM, 1:1, caliper = 0.2), early response to treatment, survival outcomes, and treatment-related adverse events (TRAEs) were assessed. Subgroup analyses, prognostic analyses, and sensitivity analyses were also conducted. RESULTS: After PSM, 86 patients were analyzed (43 per group). The median follow-up duration was 20.8 months (interquartile range [IQR], 12.1-27.1 months). Early response assessment after two treatment cycles showed no significant difference between the BsAb-Combo and PD-1i-Combo groups (ORR 60.5% vs. 51.2%, p = 0.385; DCR 95.3% vs. 97.7%, p = 1.000). The mPFS was 20.2 months (95% CI, 18.6-not reached) in the BsAb-Combo group and 27.2 months (95% CI, 12.6-not reached) in the PD-1i-Combo group (HR = 0.88, 95% CI 0.44-1.75; log-rank p = 0.708). Grade 3-5 decreased white blood cell count was more frequent with PD-1i-Combo (37.2% vs. 9.3%, p = 0.002), whereas all-grade diarrhea was more common with BsAb-Combo (46.5% vs. 25.6%, p = 0.043). Subgroup analyses suggested that persistent/recurrent with distant metastases tended to benefit more from BsAb-Combo. In multivariate Cox models, ECOG Performance Status 2, lung metastasis, and ≥ 1-year maintenance therapy were independent prognostic factors for PFS. CONCLUSION: BsAbs (PD-1/CTLA-4) combined with platinum-based chemotherapy ± bevacizumab demonstrated comparable efficacy and safety to PD-1 inhibitors and showed a favorable hazard-ratio trend. Hypothesis-generating signals observed in select subgroups, such as those with persistent or recurrent disease with distant metastases, warrant confirmation in prospective studies with extended follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, 210009, China.
- Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, 210009, China. hexia2021@njmu.edu.cn.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210009, China. hexia2021@njmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Wu, Y., Huang, J., Zong, D., & He, X. (2025). Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04204-y
Vancouver
Wang X, Wu Y, Huang J, Zong D, He X. Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04204-y
BibTeX
@article{Wang2025,
author = {Wang, Xin and Wu, Yaqin and Huang, Jian and Zong, Dan and He, Xia},
title = {Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04204-y}
}
EUVIMED